MoonLake Immunotherapeutics (MLTX) Misses Q2 EPS by 15c
Tweet
Share
E-mailGet Alerts MLTX Hot Sheet
Join SI Premium – FREE
MoonLake Immunotherapeutics (NASDAQ: MLTX) reported Q2 EPS of ($0.87), $0.15 worse than the analyst estimate of ($0.72).
For earnings history and earnings-related data on MoonLake Immunotherapeutics (MLTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance
- Netskope, Inc. (NTSK) Tops Q2 EPS by 4c, Offers Guidance
- Barrick Mining said to delay IPO of American gold business to 2027
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
